CA2418030A1 - Isolation of glucan particles and uses thereof - Google Patents

Isolation of glucan particles and uses thereof Download PDF

Info

Publication number
CA2418030A1
CA2418030A1 CA002418030A CA2418030A CA2418030A1 CA 2418030 A1 CA2418030 A1 CA 2418030A1 CA 002418030 A CA002418030 A CA 002418030A CA 2418030 A CA2418030 A CA 2418030A CA 2418030 A1 CA2418030 A1 CA 2418030A1
Authority
CA
Canada
Prior art keywords
process according
glucan particles
mannoprotein
obtainable
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002418030A
Other languages
French (fr)
Other versions
CA2418030C (en
Inventor
Martin Sauter
Stefan Freimund
Hans Dutler
Othmar Kappeli
Ahmad Al-Ghazawi
Eugen Schwarz
Lutz Thomas
Helmut Schoberl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABAC R&D AG
Original Assignee
Martin Sauter
Stefan Freimund
Hans Dutler
Othmar Kappeli
Ahmad Al-Ghazawi
Eugen Schwarz
Lutz Thomas
Helmut Schoberl
Abac R&D Ag
Abac R&D Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin Sauter, Stefan Freimund, Hans Dutler, Othmar Kappeli, Ahmad Al-Ghazawi, Eugen Schwarz, Lutz Thomas, Helmut Schoberl, Abac R&D Ag, Abac R&D Gmbh filed Critical Martin Sauter
Publication of CA2418030A1 publication Critical patent/CA2418030A1/en
Application granted granted Critical
Publication of CA2418030C publication Critical patent/CA2418030C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00—Aspects relating to sorbent materials
    • B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/52—Sorbents specially adapted for preparative chromatography

Abstract

The present invention relates to the isolation of novel glucan particles but also to mannoprotein from natural sources such as yeast cell walls, novel isolation methods, and the use of products thereof.

Claims (28)

1. Glucan particles with a molecular weight (M W or M N) of more than 100 000 after solubilization by carboxymethylation having preserved porous and fibrous structural properties.
2. Glucan particles according to claim 1 with a size range of 0.1 to 25 micrometers, preferably 0.5 to 15 micrometers, and most preferably 2 to 10 micrometers.
3. Glucan particles according to claims 1 or 2, which are insoluble in water and in most of the known organic solvents, having activated pores and which are showing an increased stability at high pH-values.
4. Glucan particles according to claims 1 to 3 with gel forming proper-ties.
5. Glucan particles according to at least one of the claims 1 to 4 form-ing a stable gel in organic solvents or acidified water, when an aqueous suspension of these particles is heated to a temperature higher than 80°C.
6. Process for isolating glucan particles from unicellular organisms or glucan-containing plants, comprising the steps a) extracting mannoproteins with water at temperatures above the boiling point of water and/or treatment of the raw materials or of the product from step a) b) with proteases or by non-denaturating chemical means for the removal of proteins and/or c) with lipases, or by solvent extraction for the removal of lipids on condition that steps b) and c) may be proceeded in any sequence and if necessary in dependence on the starting material one or two steps may be left out.
7. Process according to claim 6 comprising as step a) treatment with water at temperatures above the boiling point of water under ele-vated pressure and adjusted pH for extracting mannoprotein.
8. Process according to at least one of the claims 6 or 7 wherein in step a) mannoproteins are extracted from an aqueous cell wall sus-pension in the concentration range of 1 - 20 % by weight, preferably 10 - 20 %, most preferably 13 -17 %, with adjusted pH in the range of 5 - 9, preferably pH 6 - 8 , most preferably pH 6.5 - 7.5, at a tem-perature in the range of 120 -130°C for a defined period of time in the range of 0.1 - 24 hours, preferably 1 - 10 hours, most preferably 3 - 7 hours under elevated pressure.
9. Process according to at least one of the claims 6 - 8, wherein the mannoprotein is removed from the recovered aqueous solution (water extracts) from step a) by adding and mixing with an alcohol and precipitating.
10. Process according to claim 9 wherein the alcohol is selected from the group methanol, ethanol, propanol, and butanol.
11. Process according to claim 6 comprising as step b) treatment with proteases after pH adjustment at optimal level for the removal of contaminating proteins.
12. Process according to claim 6 wherein in step b) protein contami-nants are extracted either with aqueous alkaline solution selected from the group sodium carbonate and sodium hydrogen carbonate at low concentration and low temperature or with sodium dodecylsulfate at a concentration in the range of 0.1 - 5 by weight, preferably 1 - 3 % by weight, most preferably 1.5 - 2.5 by weight.
13. Process according to claim 6 comprising as step c) treatment with lipases after pH adjustment at optimal level for removal of contami-nating lipids.
14. Process according to claim 6 wherein in step c) lipid contaminants are extracted either with organic solvents, that are miscible with water, selected from the group acetone ethanol, methanol, isopro-panol and butanol or mixtures thereof;
or with organic solvents that are not miscible with water, selected from the group isobutylketone, hexane, chloroform, methylenechloride, tetrachloroethylene and ethylacetate or mixtures thereof, or with mixtures of organic solvents that are miscible with water with organic solvents that are not miscible with water;
or extraction with supercritical CO2, or extraction with supercritical CO2 and organic solvents as modifiers.
15. Process according to claims 6 and 14 wherein in step c) lipid con-taminants are extracted with a mixture of methanol and chloroform in a ratio of volume of 1 : 1 or of hexane and isopropanol in a ratio of volume of 3 : 2.
16. Mannoprotein obtained from step a) according to at least one of the claims 6 - 10.
17. Glucan particles obtainable by a process according to at least one of the claims 6 - 8, 11 - 15.
18. Glucan particles obtainable by a process according to claims 6 - 8 by protease treatment after extracting mannoproteins with water.
19. Glucan particles obtainable by a process according to at least one of the claims 6 - 8, 11, 13, by lipase treatment or solvent extraction of ter extracting mannoprotein with water and removing protein con-taminants with protease.
20. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 as adsorbents and carriers, as chroma-tographic active material or as adsorbents for toxic environmental compounds.
21. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of pharmaceutical or cosmetic formulations or as additive in food and feed or in products needed in agriculture in crop protection.
22. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of pharmaceutical formulations with immune system activating properties.
23. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of pharmaceutical formulations with antitumor activity or for administration in combination with chemotherapy or di-alysis.
24. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of pharmaceutical formulations to improve the host-defences to bacterial or virus infections.
25. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of pharmaceutical formulations with prophylactic activity against diseases of age.
26. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of formulations with cholesterol reduction activity.
27. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of formulations with an glucose regulating effect.
28. Use of glucan particles according to at least one of the claims 1 - 5, 17 - 19 or obtainable from a process according to at least one of the claims 6 - 8 or 11 - 15 and/or mannoprotein according to claim 16 for the preparation of formulations with improving effects on cardio-vascular diseases, on autoimmune conditions like HIV, arthritis, lu-pus, allergic asthma or multipe sclerosis.
CA2418030A 2000-08-03 2001-07-31 Isolation of glucan particles and uses thereof Expired - Lifetime CA2418030C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116764.2 2000-08-03
EP00116764 2000-08-03
PCT/EP2001/008851 WO2002012348A2 (en) 2000-08-03 2001-07-31 Isolation of glucan particles and uses thereof

Publications (2)

Publication Number Publication Date
CA2418030A1 true CA2418030A1 (en) 2002-02-14
CA2418030C CA2418030C (en) 2010-10-26

Family

ID=8169434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2418030A Expired - Lifetime CA2418030C (en) 2000-08-03 2001-07-31 Isolation of glucan particles and uses thereof

Country Status (5)

Country Link
US (2) US20040054166A1 (en)
EP (1) EP1414865B1 (en)
AU (1) AU2001279796A1 (en)
CA (1) CA2418030C (en)
WO (1) WO2002012348A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354355T1 (en) * 2001-04-27 2007-03-15 Ajinomoto Kk A DISPERSION OF HIGHLY FINE PARTICLES CONTAINING BETA-GLUCAN, A CORRESPONDING PRODUCTION PROCESS AND THE USE OF THE DISPERSION
SI1711058T1 (en) 2004-01-23 2022-02-28 Eden Research Plc, Methods of killing nematodes comprising the application of a terpene component
DK1753529T3 (en) * 2004-05-20 2013-11-11 Eden Research Plc Composition containing a hollow glucan particle or hollow cell wall particle encapsulating a terpene component, methods of preparing and using them
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
JP5302537B2 (en) 2004-09-17 2013-10-02 ユニバーシティ オブ マサチューセッツ Compositions for lysosomal enzyme deficiency and their use
AU2005318194B2 (en) * 2004-12-23 2010-08-19 Dsm Ip Assets B.V. New mannoprotein with full solubility in wine and its application in the stabilisation of wine
WO2006067147A1 (en) * 2004-12-23 2006-06-29 Dsm Ip Assets B.V. Process to improve activity of mannoprotein as wine stabiliser
US20060263415A1 (en) * 2005-05-05 2006-11-23 Sensient Flavors Inc. Production of beta-glucans and mannans
US9439416B2 (en) * 2005-11-30 2016-09-13 Eden Research Plc Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
EP1954129A1 (en) 2005-11-30 2008-08-13 Eden Research Plc Terpene-containing compositions and methods of making and using them
TW200900053A (en) 2007-02-21 2009-01-01 Biotec Pharmacon Asa Medical uses of glucans
FR2921260B1 (en) * 2007-09-25 2012-08-24 Lesaffre & Cie USE OF A NEW NATURAL AGENT IN COSMETIC COMPOSITIONS
CA2704056A1 (en) 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
ITPD20080022A1 (en) 2008-01-23 2009-07-24 Enologica Vason Srl PRODUCTION METHOD OF A PRODUCT FOR TARTARIC WINE STABILIZATION, PRODUCT FOR STABILIZATION AND STABILIZATION PROCEDURE THROUGH THE ABOVE PRODUCT.
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
BRPI0900639C1 (en) * 2009-02-13 2011-12-20 Hebron Farmaceutica Pesquisa Desenvolvimento E Inovacao Tecnologica Ltda pharmaceutical composition and use thereof for treatment and / or prevention of respiratory tract diseases
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
JP6060071B2 (en) 2010-03-24 2017-01-11 アールエックスアイ ファーマシューティカルズ コーポレーション RNA interference in skin and fibrosis applications
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
US9603858B2 (en) 2010-11-29 2017-03-28 Raisio Nutrition Ltd. Compositions for preventing and treating an immune system disorder
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
JP6883987B2 (en) 2013-12-04 2021-06-09 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Methods for wound healing procedures utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
CA2947619A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR20230037676A (en) 2014-09-05 2023-03-16 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180026739A (en) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 A nucleic acid molecule targeting superoxide dismutase 1 (SOD1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
US11384160B1 (en) 2021-07-30 2022-07-12 Tissue repair ltd Method of making a beta glucan compound
US11572420B1 (en) 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795716A (en) 1972-02-22 1973-08-21 Glaxo Lab Ltd THERMOSTABLE ENZYMATIC COMPOSITIONS
JPS5621532B2 (en) * 1972-06-15 1981-05-20
US3867554A (en) 1972-11-29 1975-02-18 Robert William Sucher Yeast glycan and process of making same
DE2646879A1 (en) * 1975-10-21 1977-05-05 Takeda Chemical Industries Ltd MATRIX OF A BETA-1,3-GLUCANGEL, INSOLUBLE IN WATER, AND METHOD FOR MANUFACTURING IT
JPS5366442A (en) * 1976-11-18 1978-06-13 Takuma Sasaki Antitumors
JPS55709Y2 (en) 1977-09-07 1980-01-10
JPS55709A (en) * 1978-04-17 1980-01-07 Kirin Brewery Co Ltd Novel polysaccharide and its use
SE456911B (en) 1983-12-19 1988-11-14 Olle Larm WATER-SOLUBLE, AMINATED BETA-1,3-BUNDLE D-GLUCAN AND MACROPHAG STIMULATING COMPOSITION CONTAINING ITS SAME
JPS60196195A (en) * 1984-03-21 1985-10-04 Dainippon Seito Kk Preparation of yeast glucan
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5037972A (en) 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5250436A (en) 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
JPS6240262A (en) * 1985-08-16 1987-02-21 Sanshu Seika Kk Health food containing immunoenhancing substance and sod-like substance and production thereof
US4795653A (en) 1986-06-16 1989-01-03 Bommarito Alexander A Dietary fiber and method of making
US4962094A (en) * 1988-10-28 1990-10-09 Alpha Beta Technology, Inc. Glucan dietary additives
IT1232310B (en) * 1989-09-04 1992-01-28 Consiglio Nazionale Ricerche PROCESS FOR THE PREPARATION OF A PRODUCT CONTAINING GLUCAN FROM CANDIDA ALBICANS BMM-12
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US6143731A (en) 1989-10-20 2000-11-07 The Collaborative Group, Ltd. Glucan dietary additives
US6020324A (en) * 1989-10-20 2000-02-01 The Collaborative Group, Ltd. Glucan dietary additives
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
GB9022560D0 (en) * 1990-10-17 1990-11-28 G B Biotechnology Limited Processing of waste
EP0503880B1 (en) * 1991-03-14 1997-10-01 Tsuyoshi Masumoto Amorphous magnesium alloy and method for producing the same
JPH055709A (en) 1991-06-27 1993-01-14 Matsushita Electric Ind Co Ltd Screen inspection device
IT1256035B (en) * 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche IMMUNOSTIMULATING ACTIVITY GLUCANS
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
EP0790316A3 (en) 1996-02-16 1999-02-10 Quest International B.V. Emulsifier from yeast
DK1079696T3 (en) * 1998-04-17 2007-07-02 Alltech Inc Compositions for removing mycotoxins from feed

Also Published As

Publication number Publication date
WO2002012348A3 (en) 2002-04-25
US20040054166A1 (en) 2004-03-18
AU2001279796A1 (en) 2002-02-18
WO2002012348A2 (en) 2002-02-14
EP1414865B1 (en) 2014-04-09
US20060134759A1 (en) 2006-06-22
EP1414865A2 (en) 2004-05-06
CA2418030C (en) 2010-10-26
US9187575B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
CA2418030A1 (en) Isolation of glucan particles and uses thereof
US9249235B2 (en) Processes for isolating chitin and chitosan from fungal biomass
Antunes-Valcareggi et al. Enzymatic hydrolysis of blue crab (Callinectes Sapidus) waste processing to obtain chitin, protein, and astaxanthin-enriched extract
EP3974044B1 (en) Process for the aqueous extraction of biosurfactants from corn steep liquor
JP2002037739A (en) Immunomodulator
KR20190064093A (en) Cosmetic Composition for Moisturizing Skin Comprising Gracilaria Extract
ATE303811T1 (en) PRODUCTION OF POLYGALACTURONIDES AND THEIR USE AS FOOD ADDITIVES
US5612038A (en) Product with lipolytic activity and its method of preparation
CN105495282A (en) Application of encapsulated cryptococcus laurentii to removal of patulin
KR102579011B1 (en) Method for purifying sophorolipid
EP1121453B1 (en) Heteropolysaccharide produced by an agrobacterium radiobacter
Thuy et al. Deproteinization in purification of exopolysaccharide from Ophiocordyceps sinensis olive oil-stimulated culture.
MXPA01004156A (en) Azadirachtin compounds extracted from azadirachta indica, compositions and use thereof as insecticidal.
JPH0742322B2 (en) Acrylglycan of Klebsiella bacterium, method for producing the same and drug comprising the same
CN103289968B (en) From the water-soluble extracting liquid of sweet potato, be separated and prepare the method for polyphenoloxidase, beta-amylase and storage protein
JP4308714B2 (en) Process for producing natural product-derived glyceroglycolipid
CA2370194C (en) Heteropolysaccharide produced by pseudomonas sp
KR102139867B1 (en) Preparation Method of Aplysia kurodai Peptides with High Yield Using Enzyme
KR20180128560A (en) Preparation Method of Sea Slug Peptides with High Yield Using Enzyme
KR970032502A (en) Phalanx extract and its manufacturing method
Osho et al. Prospects of Biocatalyst Purification Enroute Fermentation Processes
JPH0784477B2 (en) Twain manufacturing method
CN114774488A (en) Production method of low-endotoxin gamma-polyglutamic acid
JPH0365956B2 (en)
KR950003297A (en) Separation and Purification of Separantin and Alkaloids Containing It from the Plant of the Plant

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210803